Theseus Pharmaceuticals (THRX) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free THRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative February 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | marketbeat.comTrading was temporarily halted for "THRX" at 07:02 PM with a stated reason of "News pending."January 30, 2024 | finance.yahoo.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRJanuary 13, 2024 | marketbeat.comShort Interest in Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Drops By 37.4%Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 585,500 shares, a drop of 37.4% from the December 15th total of 936,000 shares. Based on an average daily volume of 690,600 shares, the short-interest ratio is presently 0.8 days. Currently, 3.8% of the company's shares are sold short.December 31, 2023 | businesswire.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 29, 2023 | finance.yahoo.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?December 29, 2023 | marketbeat.comTheseus Pharmaceuticals, Inc. (NASDAQ:THRX) Short Interest UpdateTheseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 936,000 shares, a drop of 42.2% from the November 30th total of 1,620,000 shares. Based on an average daily volume of 620,000 shares, the short-interest ratio is presently 1.5 days. Currently, 6.1% of the company's shares are short sold.December 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNDecember 22, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | markets.businessinsider.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | tmcnet.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | finance.yahoo.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNovember 27, 2023 | msn.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | markets.businessinsider.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraNovember 27, 2023 | finance.yahoo.comTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNovember 14, 2023 | finance.yahoo.comTheseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce ReductionNovember 14, 2023 | bizjournals.comTwo years after IPO, Theseus Pharmaceuticals lays off most its staff, explores saleNovember 14, 2023 | benzinga.comThinking about buying stock in Theseus Pharmaceuticals, Vuzix, Jaguar Global Growth, Fisker, or Cardio Diagnostics Holdings?November 13, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 35% on Workforce Reduction, Strategic Alternatives ConsiderationNovember 13, 2023 | msn.comTheseus Pharmaceuticals explores strategic options; cuts workforce by 72%November 13, 2023 | finance.yahoo.comTheseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNovember 13, 2023 | marketbeat.comTrading was temporarily halted for "THRX" at 04:11 PM with a stated reason of "News pending."November 7, 2023 | morningstar.comTheseus Pharmaceuticals Inc THRXNovember 7, 2023 | finance.yahoo.comTheseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceOctober 9, 2023 | finance.yahoo.comTheseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth PlansSeptember 29, 2023 | msn.comTheseus Pharmaceuticals: Picking Up The Pieces After A Lead FailureAugust 14, 2023 | marketbeat.comTheseus Pharmaceuticals, Inc. Expected to Earn Q3 2023 Earnings of ($0.37) Per Share (NASDAQ:THRX)Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Stock analysts at Wedbush boosted their Q3 2023 earnings estimates for shares of Theseus Pharmaceuticals in a report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings perAugust 11, 2023 | finance.yahoo.comDown -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)August 11, 2023 | marketbeat.comTheseus Pharmaceuticals, Inc. (NASDAQ:THRX) Expected to Post Q1 2024 Earnings of ($0.33) Per ShareTheseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Wedbush issued their Q1 2024 earnings estimates for Theseus Pharmaceuticals in a research report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.33) per share for thAugust 10, 2023 | markets.businessinsider.comDeciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: AnalystAugust 10, 2023 | finance.yahoo.comTheseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial ResultsJuly 21, 2023 | benzinga.comTheseus Pharmaceuticals Recent Insider ActivityJuly 20, 2023 | benzinga.comMassive Insider Trade At Theseus PharmaceuticalsJuly 20, 2023 | benzinga.comDirector of Theseus Pharmaceuticals Makes $1.46M BuyJuly 18, 2023 | finance.yahoo.comAfter Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)July 17, 2023 | benzinga.comThinking about buying stock in AMC Entertainment, Archer Aviation, Theseus Pharmaceuticals, Quantumscape, or Acumen Pharmaceuticals?July 17, 2023 | msn.comTheseus (THRX) Falls 72% on Decision to Discontinue GIST StudyJuly 14, 2023 | marketwatch.comTheseus Pharma Shares Fall 71%, Company Halts Development of Tumor Drug THE-630 in Patients with GISTJuly 14, 2023 | markets.businessinsider.comSetback For Theseus Pharmaceuticals: Analysts Cut Price Targets But Remain Bullish On StockJuly 14, 2023 | marketbeat.comTheseus Pharmaceuticals (NASDAQ:THRX) Price Target Lowered to $7.00 at Cantor FitzgeraldCantor Fitzgerald dropped their target price on shares of Theseus Pharmaceuticals from $23.00 to $7.00 and set an "overweight" rating for the company in a research report on Friday.July 14, 2023 | msn.comWhy Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketJuly 14, 2023 | msn.comTHRX Tanks after Pausing Trial of Lead Cancer CandidateJuly 14, 2023 | markets.businessinsider.comDose-Limiting Toxicities: Theseus Pharma Terminates THE-630 Study For Gastrointestinal CancerJuly 14, 2023 | markets.businessinsider.comAnalyst Expectations for Theseus Pharmaceuticals's FutureJuly 13, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Terminates Development Of THE-630July 13, 2023 | marketwatch.comTheseus Pharma Shares Plummet 73% on Discontinued Study, THE-630 DevelopmentJuly 13, 2023 | benzinga.comTheseus Pharmaceuticals Shares Halted, News Pending Get Theseus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter. Email Address What President Biden's new law means for investors (Ad)What's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it. This expert just went public with all the details, including which stocks to jump on immediately. THRX Media Mentions By Week THRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THRX News Sentiment▼0.000.42▲Average Medical News Sentiment THRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THRX Articles This Week▼01▲THRX Articles Average Week Get Theseus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OM News CGEN News HITI News GALT News GLSI News DRTS News GNFT News ADVM News LFCR News OBIO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THRX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
